Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Blue - you give patient a call and report back to us. I have done my good deed reporting back what I heard and it is someone else's turn.
Tilator - look at Chinese partner they have... I am sure a company that big has complete control of the government body. China is very corrupt and ipci has big brother on their side.
The path for Keppra and Gluco to market is absolutely clear now.
blue- Lets hope they complete the testing right away. But no reason not to sell 15 and 30 mg versions as those are high volume runners.
This was taken from another site and it is of significance. I have to credit that individual for posting this:
2017 China FDA reforms
These days, there can be no doubt of the necessity of engaging with the world’s second-largest pharmaceuticals market, and all the top drugmakers run either wholly-owned facilities or joint ventures in the country.
The latest set of changes at the CFDA look likely to accelerate competition from big international pharma.
"...clinical trials conducted outside of the country will now be admitted as part of regulatory filings in China."
I just can't believe that most of you do not realize how significant this Chinese manufacturing development is... Think about this:
Is agreement for PAR Focalin XR just for US? I think it is. Is agreement for Seroquel XR with MNK just for US? I think it is. They should be able to launch those products right a way in China. Also Keppra and Gluco too in China as well as US.
I really do believe this Chinese partnership is a major development. I am happy to see this. As it now is clear how Keppra and Gluco will be produced. I always said the Toronto facility was not the right fit for producing high volume, low cost drugs. But a plant in China, sure is...
Also, this development probably opens doors to other markets- Namely China and Asia. Last time I checked lots of people over there...
Certainly this is big news, that should translate to revenue soon.
I can't wait to hear the details of this agreement. Looks to me to be some type of contract manufacturing partnership with some Chinese investors. The article did not disclose ownership of buildings, equipment, etc. So I await the details on this.
Tilator - I have been kind enough to share what I heard from ipci directly. Contact cfo if you want confirmation. But your last post twisted my words... What I said ipci said was:
1. Podras first human test results 1h2018.
2. They were optimistic more than one approval in 3-6 months.
All - I will give a summary of my impressions some time later this weekend, when I have time. But overall I have a very good feeling that things are coming together.
In full disclosure, two more items :
1. They are optimistic more than one approval will come through in 3-6 months.
2. They are not currently worried about delisting. The can file extensions and feel that there are things happening within this time frame that will likely bring them to compliance.
Mopar - I just wanted to share so everyone can have real info and not just the bs and misleading information that some present.
I spoke to IPCI today. Here is the update:
1. Rexista HAP studies have not started. FDA has not approved protocol yet. IPCI asked for a meeting in November and FDA was supposed to meet with them within 30 days but has not. They do feel they will complete studies quickly though. They still expect to resubmit NDA in July/August 2018 timeframe and feel they are on track for 2019 approval. They noted that the Purdue litigation goes to court in October 2018, so even if they had an approval now, they could do nothing with it.
2. PODRAS human studies have not started. However they are working hard to resolve hoops needed to jump through to commence these. They are shooting at having PODRAS human test results 1H2018.
wimike- I think news is coming... But not today. If I were to guess what it will be. I am thinking approval in coming weeks. But just a guess- based on past historical chart that shows excessive volume(millions) always preceding an approval for no good reason. Very nice to be in the news way before everyone else. At one time I thought that was insider trading but now I know it as business as usual.
Sadly I do not think there will be news today. But maybe in coming weeks and months. All I can think is the action today was nothing more than the MM covering and wash trading. I hope I am wrong but that is what I think it is. So if no news today, I guess this might signal some news somewhat soon. Lets hope sooner rather than later.
Impact- when can we expect the news on PODRAS?
wimike- Take a look at the historical chart. There was always news leaked and someone front running the approvals. Sad but true. I don't know what this is for sure, but volume seems to indicate more than just the normal games.
Doog- Good news... Let's hope so. IPCI's new motto: If it wasn't for bad luck we'd have no luck at all!
Fabius- One of the big problems is the people shorting are the offering buyers and the market makers. The thing that really irks me in all this is these same people are always tipped off about news early and it allows them to cover. You have to wonder who is the leak in the hull that constantly feeds these guys info. This is by definition insider trading but the SEC allows this to go on everywhere. Not only with IPCI.
Doog - I think tilator is referring to that no nda has been filed on regabatin and ipci really only has one nda in progress.
Doog Agreed... If they are actually doing anything... It would be nice if they inform us.
Would be nice to see IPCI get up off the ground and back on the horse and start those damned HAP studies.
Cironman- I think some of the shorts are the market makers and those associated with them. The shorts are also the people that buy the offerings and short sell. They have a get out of jail free card with the warrants attached to the offerings. Pretty much nothing to lose. That is why offerings with warrants are so bad.
Don't waste your time with kirin Smith. Hopefully they did let him go as he brings nothing to the table. Try sending to the generic ipci email on site and say it is for cfo patient.
Impact - sounds like you have inside information that is not public yet.
Swe77- I agree about doubling or tripling your position. There should be at least parts of 2018 when pps is substantially higher. At least that is what I think...
Yes happy holidays to all on here!
Doog- I agree that partnerships could happen. I just don't have a feel of what and when. The stuff I posted is just the very obvious stuff the company is working towards. Happy holidays to you Doog!
This will be one of my last posts of the year. I am not expecting IPCI to announce anything this year. I don't know anything, just the vibe I am getting... But I am optimistic for 2018. Here is what I see:
1. Focalin sales will be solid and deliver about $1-1.25M per quarter or roughly $4-5M in FY 2018.
2. Seroquel sales will continue to ramp up. This will be slow but by mid 2018 I think we will be seeing some nice revenue rolling in on Seroquel.
3. There will be at least one ANDA approval early in 2018.
4. At least one additional product will be commercialized in early 2018 and by around mid 2018 CFP status may be achieved. I think this can be done with Focalin, Seroquel and one other commercialized product. No guarantees here but if either Pritiq or Lamictal is approved in early 2018, then I would say this is for certain.
5. IPCI will complete the Rexista HAP studies roughly 3/4 the way through 2018. They will then ready to resubmit.
6. IPCI will hopefully resolve Purdue lawsuit.
7. PODRAS first clinical studies on humans will commence some time in 2018. Hopefully we will hear of results some time in 2018.
I know there is more that can and may happen, but I think that is a pretty good timeline on what at a minimum should happen with proper execution.
Happy Holidays All!
Isn't about time for one of those phony PRs regarding a buyout or big time partnership? We haven't seen that trick in a while and it is long overdue! LOL
wimike- I also do not believe for one second the company is a takeover target. In order to take over, they would have to be able to pick up a good number of shares. People are not selling right now. The shares traded every day are the same shares that are traded and shorted, over and over and over. In order for someone to be able to accumulate say 10M shares, the price would have to go up substantially. As that is when actual sales would start to happen. Trading the same 500K shares over and over again will not do that.
Fred- I am being told for Seroquel XR the data on Symphony is NOT what is being reported on Bloomberg. I am not sure what Bloomberg does with the raw Symphony data but I am being told they are different...
Doog- Everything that I see tells me we should be last quarter by a hair. Here's to hoping for closer to $1.5M that $1M!
Doog- We do know that Seroquel XR sales have increased. With all that I know now, I think most of last quarter was Focalin sales which were probably about $1M, we also had $75K from MNK amortization. So what I see for Q4 is:
Focalin XR- $0.9-1.1M
Seroquel XR- $150-300K
MNK Amortization- $75K
Total- $1.125-1.475M
I did not ask ipci about focalin. But they should be around last quarter numbers or possibly slightly higher. But just a hair higher. You keep asking me what they said on seroquol... How many times do I have to tell you the same thing... The numbers so far are very low. That is my interpretation of what was said.
Blue- I guess I am not as optimistic as you. I greatly hope your right, but I think it is going to be a push just to hit $1.5M. I think Seroquel $'s are still really low and until MNK gets some of the big contracts, they will stay that way.
Blue- let's hear your estimates. Q3 seroquol revs were pretty much nothing in my opinion. Q3 came in at $1.2M so this Q we should be a little higher. Let's hope they hit $1.5M.
Ipci Q4 revenue will be better than Q3 most likely. But not by much. Focalin will be about $1M while seroquol will be a couple hundred thousand. I estimate 1-1.5M.
Blue - Mnk had a slow launch and large contracts got locked up. But they feel numbers will continue to improve and Mnk should be able to bid some of those large contracts soon.
Blue- I learned that what is being reported as $ for seroquol xr on Bloomberg is way too high. That often these estimates are based on list price and actual sell price for supplying company can vary by who and how it is sold. But one thing is for certain, sell price is way lower than list price. Also, I heard that there is no way the numbers on Bloomberg actually correlate to sales.